Discover our latest clinical research

Featured Publication

Our rigorous clinical research shows the Mirvie RNA platform can predict preeclampsia and preterm birth months in advance.1,2,3

Nature Magazine Logo

Mirvie Announces Completion of Enrollment of 10,000 Person Landmark Research Study for Pregnancy Health

South San Francisco - CA November 14, 2023

Mirvie, a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.

Read More
Nature Magazine Logo

Mirvie becomes first RNA-based pregnancy health-focused company to receive clinical laboratory improvement amendments (CLIA) certification

South San Francisco, CA - September 26, 2023

Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced its South San Francisco-based laboratory has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.

Read More
Nature Magazine Logo

Mirvie receives $4.6 million grant to study objective prediction of preeclampsia in Sub-Saharan Africa

South San Francisco, CA - August 2, 2023

Mirvie’s commitment to global maternal health supported by funding from Bill & Melinda Gates Foundation for study to predict preeclampsia, a leading cause of maternal mortality worldwide using the Mirvie RNA platform

Read More
Nature Magazine Logo

First comprehensive care plan to prevent preeclampsia published in the American Journal of Obstetrics and Gynecology

South San Francisco, CA -  April 28, 2023

Recommendations for high-risk expecting parents and health care providers to promote the prevention of preeclampsia, a leading cause of pregnancy-related death in the United States

Read More
Nature Magazine Logo

First ever “Future of Pregnancy Health” report reveals 9 out of 10 new or expecting moms want more information about their individual risk of pregnancy complications to optimize prevention

South San Francisco, CA - November 8, 2022

Mirvie's report spotlights urgent education opportunities as only 1 in 10 pregnant individuals or those who gave birth could correctly identify all the most common preeclampsia warning signs and symptoms

Read More
Nature Magazine Logo

Mirvie expands leadership team with appointment of Alison Cowan, M.D. as Head of Medical Affairs

South San Francisco, CA - AUGUST 30, 2022

Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the appointment of Alison Cowan, M.D., M.S.C.R. as Head of Medical Affairs. Dr. Cowan will guide Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.1

Read More
Nature Magazine Logo

Mirvie raises $60 million funding round to shape the future of pregnancy health

South San Francisco, CA - May 17, 2022

Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced it has raised a total of $90 million to date following the close of its Series B funding. The financing was led by Decheng Capital with additional funding from funds and accounts managed by BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield as well as a debt facility with Comerica Bank. The funding will support Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is the first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.

Read More
Nature Magazine Logo

Mirvie receives FDA Breakthrough Device Designation for first test designed to indicate risk of preeclampsia months before symptoms occur

South San Francisco, CA - May 3, 2022

Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the company received U.S. Food and Drug Administration (FDA) Breakthrough Device designation for its test to indicate a woman’s individualized risk of developing preeclampsia before symptoms occur. The test is powered by the proprietary Mirvie RNA platform, which is designed to predict the risk of unexpected complications by revealing the underlying biology of each pregnancy.

Read More
Nature Magazine Logo

Study published in The American Journal of Obstetrics and Gynecology shows the Mirvie RNA Platform is first to predict preterm birth by revealing the underlying biology of each pregnancy

South San Francisco, CA - April 13, 2022

Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the publication of a study in the American Journal of Obstetrics and Gynecology, a leading obstetrics and gynecology medical journal. The results demonstrate the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy. The breakthrough research shows the platform can predict the condition months before symptoms occur and identify distinct biological pathways driving its development.

Read More
Nature Magazine Logo

Late-breaking data presented at SMFM 2022 annual meeting shows the Mirvie RNA Platform is first to reveal the underlying biology of preterm birth

South San Francisco, CA - February 4, 2022

Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced data presented at the Society for Maternal-Fetal Medicine 42nd Annual Pregnancy Meeting (SMFM 2022) demonstrates the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy. The breakthrough research shows the platform can predict the condition months before symptoms occur and identify distinct biological pathways driving its development.

Read More